Evidence map›Paper›PMID 37111383›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Examination of Risk Factors and Expression Patterns of Atypical Femoral Fractures Using the Japanese Adverse Drug Event Report Database: A Retrospective Pharmacovigilance Study.

Shinya Toriumi, Ryuji Mimori, Haruhiko Sakamoto, Hitoshi Sueki, Munehiro Yamamoto, Yoshihiro Uesawa

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shinya ToriumiDepartment of Medical Molecular Informatics, Meiji Pharmaceutical University, Kiyose 204-8588, Japan.ORCID 0000-0001-5521-0820
Ryuji MimoriDepartment of Pharmacy, National Hospital Organization Kanagawa Hospital, Hadano 257-8585, Japan.
Haruhiko SakamotoDepartment of Pharmacy, National Hospital Organization Kanagawa Hospital, Hadano 257-8585, Japan.
Hitoshi SuekiDepartment of Orthopedic Surgery, National Hospital Organization Kanagawa Hospital, Hadano 257-8585, Japan.
Munehiro YamamotoDepartment of Orthopedic Surgery, National Hospital Organization Kanagawa Hospital, Hadano 257-8585, Japan.
Yoshihiro UesawaDepartment of Medical Molecular Informatics, Meiji Pharmaceutical University, Kiyose 204-8588, Japan.ORCID 0000-0002-5773-991X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atypical femoral fracture (AFF) is a rare complication related to the use of bisphosphonates (BPs). Herein, we analyzed the risk factors and onset patterns of AFF using the Japanese Adverse Drug Event Report database and reported the findings. First, the independent risk factors for AFF were gender (female), high body mass index, and medical history of osteoporosis, arthritis, and systemic lupus erythematosus (SLE). Drug-related risk factors for AFF included BPs (i.e., alendronic acid, ibandronic acid, etidronic acid, zoledronic acid, minodronic acid, risedronic acid), denosumab, prednisolone, lansoprazole, rabeprazole, exemestane, letrozole, eldecalcitol, and menatetrenone. Therefore, it appears that AFF is influenced by a combination of patient backgrounds and drugs, and that the risk of developing AFF is particularly high in patients with fragile bones (e.g., osteoporosis, arthritis, and SLE). Second, in the analysis of AFF onset patterns, the onset of AFF from BPs and denosumab took a long time (>1 year) to develop. Analysis using a Weibull distribution showed wear-out failure-type AFF onset for BPs and denosumab, and both osteoporosis and cancer patients with long-term administration of these drugs showed a tendency to have an increased risk of onset. AFF developed earlier in osteoporosis patients with long-term administration of BPs and denosumab than in cancer patients.

Indexed as

atypical femoral fracturebisphosphonatescancerdenosumabdisproportionality analysisepidemiological researchJapanese Adverse Drug Event Report (JADER)multiple logistic regression analysisosteoporosisWeibull distribution

Identifiers

PMID37111383
PMCPMC10144616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.